CSL Limited
CSL
Rang in Aktien
#362
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aktienkurs
$138.58
Marktkapitalisierung
$66.50B
Veränderung (1 Tag)
0.72%
Veränderung (1 Jahr)
-2.29%
Land
AU
Handel CSL Limited (CSL)
Kategorie
Healthcare
Aktien-Split-Historie für CSL Limited (CSL)
Die Aktie CSL Limited (Symbol: CSL) durchlief insgesamt 1 Aktiensplits.
Der letzte Aktiensplit fand am Oct 18, 2007 statt.
Eine CSL-Aktie, die vor dem Oct 18, 2007 gekauft wurde, entspricht heute 3 CSL-Aktien.
Der letzte Aktiensplit fand am Oct 18, 2007 statt.
Eine CSL-Aktie, die vor dem Oct 18, 2007 gekauft wurde, entspricht heute 3 CSL-Aktien.
Liste der Aktiensplits
| Jahr | Aktien-Split | Multiplikator | Kumulierter Multiplikator |
|---|---|---|---|
| 2007-10-18 | 3:1 | x3 | x3 |
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
| Unternehmen | Anzahl der Aktiensplits | Kumulierter Multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
|
| 1 | x100 |
BE
|
